Abstract 341P
Background
Lean body mass and low muscle mass are associated with survival, quality of life (QOL), and tolerance to treatment in cancer patients. Most early breast cancer patients were reported in overweight and obese nutrition status. There is still limited data evaluating the relationship between muscle mass and QOL in breast cancer patients, especially in early stages. The aim of this study is to examine the relationship between muscle mass and QOL domain in breast cancer patients before underwent chemotherapy.
Methods
A total of 80 breast cancer patients were enrolled in this study. Women breast cancer patients before they underwent chemotherapy were included in this study. Skeletal muscle mass was measured by bioelectrical impedance analysis, and it was reported as the Skeletal Muscle Index (SMI). QoL was assessed using the EORTC-QLQ-C30. The correlation between SMI and QOL was evaluated using Pearson or Spearmen correlation test based on the normality data.
Results
The mean of age was 47.39+7.07 years old. The median of body mass index (BMI) was 23.15(7.86-47.26) kg/m2. The distribution of BMI for underweight, normo-weight, overweight and obese were 5(6.3%); 33(41.3%); 16(21.1%); and 26(32.6%), respectively. Most patients were in early breast cancer 71 of 80 (88.8%). The median of SMI was 5.72(1.91-12.35). The median of QOL global health status, physical function, role function, emotional function, cognitive function, and social function domain were 66.67(0-100); 93.33(0-133.33); 100(0-133.33); 83.33(33.33-100); 100(16.67-100); and 100(0-100), respectively. The correlation between SMI and QOL global health status, physical function, role function, emotional function, cognitive function, and social function domain were (r 0.194, p 0.085); (r 0.021, p 0.851); (r 0.009, p 0.939); (r 0.061, p 0.588); (r 0.280, p 0.012); and (r 0.078, p 0.490), respectively.
Conclusions
Almost all QOL domains of breast cancer patients before underwent chemotherapy showed good results. The relationship between muscle mass and QOL in breast cancer patients before underwent chemotherapy only showed in the cognitive domain. Further studies need to be done to evaluate the physical activity and protein consumption practice with QoL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
253P - Non-Epithelial Tumours of Ovary, An Experience from Qatar
Presenter: Ammar Madani
Session: e-Poster Display Session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
271P - Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
Presenter: Cheng Hsu Wang
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session